Search

Your search keyword '"Benedict Panizza"' showing total 3 results
Start Over Author "Benedict Panizza" Publisher nature portfolio
3 results on '"Benedict Panizza"'

1. Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure

Author

Andrew Causer, Xiao Tan, Xuehan Lu, Philip Moseley, Siok M. Teoh, Natalie Molotkov, Margaret McGrath, Taehyun Kim, Peter T. Simpson, Christopher Perry, Ian H. Frazer, Benedict Panizza, Rahul Ladwa, Quan Nguyen, and Jazmina L. Gonzalez-Cruz

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Immune checkpoint inhibitor (ICI) therapy has had limited success (

Published
2023
Full Text
View/download PDF

2. Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma

Author

Corey Smith, Margaret McGrath, Michelle A. Neller, Katherine K. Matthews, Pauline Crooks, Laetitia Le Texier, Benedict Panizza, Sandro Porceddu, and Rajiv Khanna

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock for the successful implementation of ACT in clinical settings. Expression of checkpoint molecules by malignant cells can inhibit the effector function of adoptively transferred EBV-specific T cells. Here we present a novel case report of a patient with metastatic NPC who was successfully treated with a combination of EBV-specific ACT and programmed cell death-1 blockade therapy. Following combination immunotherapy, the patient showed complete resolution of metastatic disease with no evidence of disease relapse for 22 months. Follow-up immunological analysis revealed dramatic restructuring of the global T-cell repertoire that was coincident with the clinical response. This case report provides an important platform for translating these findings to a larger cohort of NPC patients.

Published
2021
Full Text
View/download PDF

3. Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma

Author

Benedict Panizza, Michelle A Neller, Pauline Crooks, Sandro V. Porceddu, Laetitia Le Texier, Katherine K. Matthews, Corey Smith, Margaret McGrath, and Rajiv Khanna

Subjects
0301 basic medicine, Cancer Research, T cell, Cell, Case Report, Cancer immunotherapy, Disease, Virus, 03 medical and health sciences, 0302 clinical medicine, medicine, Tumour virus infections, RC254-282, Tumor microenvironment, Effector, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Blockade, 030104 developmental biology, medicine.anatomical_structure, Oncology, Nasopharyngeal carcinoma, 030220 oncology & carcinogenesis, Cancer research, business
Abstract

Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock for the successful implementation of ACT in clinical settings. Expression of checkpoint molecules by malignant cells can inhibit the effector function of adoptively transferred EBV-specific T cells. Here we present a novel case report of a patient with metastatic NPC who was successfully treated with a combination of EBV-specific ACT and programmed cell death-1 blockade therapy. Following combination immunotherapy, the patient showed complete resolution of metastatic disease with no evidence of disease relapse for 22 months. Follow-up immunological analysis revealed dramatic restructuring of the global T-cell repertoire that was coincident with the clinical response. This case report provides an important platform for translating these findings to a larger cohort of NPC patients.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results